<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902023000300159</article-id>
<article-id pub-id-type="doi">10.29262/ram.v70i3.1256</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Desensibilización a deferasirox en una paciente con hemocromatosis. Reporte de un caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Desensitization to deferasirox in a patient with hemochromatosis. Case report.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguilar Hinojosa]]></surname>
<given-names><![CDATA[Nadia Karina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Figueroa Saavedra]]></surname>
<given-names><![CDATA[Evelyn Itzamara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Adscrita al servicio de Alergología  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social  ]]></institution>
<addr-line><![CDATA[Mérida Yucatán]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2023</year>
</pub-date>
<volume>70</volume>
<numero>3</numero>
<fpage>159</fpage>
<lpage>162</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902023000300159&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902023000300159&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902023000300159&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: Deferasirox es un quelante de hierro activo, indicado en el tratamiento de pacientes con hemocromatosis; sin embargo, se ha informado que el 28% de los casos puede tener reacciones adversas al fármaco. El protocolo de desensibilización para deferasirox puede ser útil cuando no se dispone de opciones terapéuticas adicionales.  Reporte de caso: Paciente femenina de 52 años, con diagnóstico de hemocromatosis, quien luego de practicarle una flebotomía se observó poca respuesta y tolerancia al tratamiento, por lo que se decidió indicar deferasirox (500 mg/día), manifestando un cuadro de urticaria y angioedema en la tercera toma. Se decidió hospitalizarla para implementar el protocolo de desensibilización con una dosis inicial de 0.6 mg, con incremento gradual hasta llegar, al tercer día, a una dosis de mantenimiento de 500 mg/día.  Conclusiones: El protocolo de desensibilización rápida con deferasirox es útil cuando no se obtiene respuesta satisfactoria con la flebotomía o no se dispone opciones de tratamiento alternativas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Deferasirox is an active iron chelator, used in the treatment of iron overload such as hemochromatosis. Up to 28% may present adverse reactions to said drug. A desensitization protocol for this drug may be useful when there are no other therapeutic options.  Case report: A 52-year-old female with a diagnosis of hemochromatosis who began treatment with phlebotomy, poor response and tolerance, so it was decided to treat with deferasirox 500 mg daily, presenting symptoms of urticaria and angioedema on the third dose. Hospitalization was decided for a desensitization protocol with an initial dose of 0.6mg with a gradual increase in the dose, reaching a maintenance dose of 500 mg per day on the third day.  Conclusion: The rapid desensitization protocol for Deferasirox is useful when there is no response or therapeutic alternative.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Deferasirox]]></kwd>
<kwd lng="es"><![CDATA[hemocromatosis]]></kwd>
<kwd lng="es"><![CDATA[alergia]]></kwd>
<kwd lng="es"><![CDATA[desensibilización]]></kwd>
<kwd lng="en"><![CDATA[Deferasirox]]></kwd>
<kwd lng="en"><![CDATA[Hemochromatosis]]></kwd>
<kwd lng="en"><![CDATA[Desensitization]]></kwd>
<kwd lng="en"><![CDATA[Allergy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<collab>Exjade (deferasirox)</collab>
<source><![CDATA[[información de prescripción]]]></source>
<year>2020</year>
<publisher-loc><![CDATA[East Hanover, Nueva Jersey ]]></publisher-loc>
<publisher-name><![CDATA[Novartis Pharmaceuticals Corporation]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="book">
<collab>Jadenu (deferasirox)</collab>
<source><![CDATA[[información de prescripción].]]></source>
<year>2020</year>
<publisher-loc><![CDATA[East Hanover, Nueva Jersey ]]></publisher-loc>
<publisher-name><![CDATA[Novartis Pharmaceuticals Corporation]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Girelli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Busti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Brissot]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cabantchik]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hemochromatosis classification: update and recommendations by the BIOIRON Society]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2022</year>
<volume>139</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>3018-29</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<collab>European Association for the Study of the Liver</collab>
<article-title xml:lang=""><![CDATA[Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on haemochromatosis]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>2022</year>
<volume>77</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>479-502</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvarenga]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Brissot]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[PCJL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Haemochromatosis revisited]]></article-title>
<source><![CDATA[World J Hepatol]]></source>
<year>2022</year>
<volume>14</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1931-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olynyk]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Ramm]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hemochromatosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2022</year>
<volume>387</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2159-70</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruner]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Deferasirox desensitization]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2016</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>171-2</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sompornrattanaphan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Krikeerati]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wongsa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Thongngarm]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful deferasirox rechallenge and treating through reaction in a patient with challenge-proven mild immediate reaction: A case report]]></article-title>
<source><![CDATA[J Asthma Allergy]]></source>
<year>2020</year>
<volume>13</volume>
<page-range>557-61</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ezzat]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Schellenberg]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Leitch]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Vickars]]></surname>
<given-names><![CDATA[LM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful tolerance of deferasirox following desensitization for significant skin rash]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2011</year>
<volume>118</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>5280</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
